Related Experiment Video

Updated: Nov 23, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

563

The Future Is P-Tau-Anticipating Direct-to-Consumer Alzheimer Disease Blood Tests

Emily A Largent1, Anna Wexler1, Jason Karlawish1,2

  • 1Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia.

JAMA Neurology
|January 4, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.7K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.7K

Related Experiment Videos

Last Updated: Nov 23, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

563
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.7K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.7K

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.2K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

590
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
590

Articles linked to this work by shared authors, journal, and citation graph.

What matters in next-generation implanted neurotechnology design? Perspectives from individuals with treatment-refractory depression.

Journal of neural engineering·2026

CONNECT4 APOE: A randomized trial of telephone versus real-time two-way videoconference for disclosure of APOE genotype results in cognitively unimpaired adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Legal Protections to Mitigate Discrimination due to Neurodegenerative Biomarker Status.

Neurology·2026

"Doing Our Best:" A Qualitative Study of Researcher Challenges Administering Neuromodulation Across Different Phenotypes.

AJOB neuroscience·2026

Study of the utility and impact of a plasma p-tau181 Alzheimer's biomarker (SUITABLE).

Alzheimer's & dementia (New York, N. Y.)·2026

Designing Consent Processes for Research With Older Adults Who May Lack Decisional Capacity: A Guide for Investigators.

Journal of the American Geriatrics Society·2026

Plasma Phosphorylated Tau 217 Percentage by Race and Ethnicity in Preclinical Alzheimer Disease.

JAMA neurology·2026

Early Pregnancy Use of Anti-CGRP Monoclonal Antibodies and Propranolol and Spontaneous Abortion Risk.

JAMA neurology·2026

Global Incidence of All-Cause Dementia: A Meta-Analysis.

JAMA neurology·2026

Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management: A Randomized Clinical Trial.

JAMA neurology·2026

Rapid Whole-Genome Sequencing in Pediatric Neurology Inpatients.

JAMA neurology·2026

Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: The OPERA I and II Randomized Clinical Trials.

JAMA neurology·2026

Comparative Analysis of Medical Device Regulatory Frameworks Across Countries.

Value in health regional issues·2026

Long forms of cardiac troponin T are independent of kidney function and improve the diagnosis of myocardial infarction.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026

Alzheimer's Disease Biomarkers Measured by Capillary Blood Collection Versus Venous Plasma and Cerebrospinal Fluid.

Annals of clinical and translational neurology·2026

Integrating Plain 2D Ultrasound and Clinical Data for Identification of At-Risk MASH: A Multicenter Proof of Concept Study.

Journal of gastroenterology and hepatology·2026

Non-invasive diagnosis of endometriosis: From expert imaging to molecular and artificial intelligence-enabled pathways.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026

[Experience in validating equipment and reagents for immunohistochemical studies in the context of changing consumables market].

Arkhiv patologii·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us